Loading...
Loading...
PSYENCE BIOMEDICAL LTD.
PSYENCE BIOMEDICAL LTD.. Spoken Alpha tracks PBMWW's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks PBMWW's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PBMWW.
curl https://api.spokenalpha.com/v1/companies/PBMWW| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.21 | $3.55 | -9.7% | +7.4% | +9.2% |
| Q4 FY2026 | $3.27 | $3.34 | -2.0% | -3.4% | -1.7% |
| Q3 FY2026 | $3.09 | $3.52 | -12.1% | +5.0% | +3.8% |
| Q2 FY2026 | $3.36 | $3.50 | -4.0% | +2.1% | +1.6% |
| Q1 FY2025 | $3.03 | $3.43 | -11.6% | +6.5% | +7.5% |
| Q4 FY2025 | $3.27 | $3.65 | -10.5% | +6.4% | +6.4% |
| Q3 FY2025 | $3.62 | $3.70 | -2.2% | +7.4% | +8.1% |
| Q2 FY2025 | $3.53 | $3.64 | -3.1% | +4.9% | +4.2% |
| Q1 FY2024 | $3.51 | $3.64 | -3.6% | -3.3% | -4.1% |
| Q4 FY2024 | $3.31 | $3.60 | -8.0% | +0.1% | -0.3% |